VivaVision Announces That VVN539 Has Been Formally Submitted for U.S. Phase II Clinical Trial Application

News

}

Home / News / Portfolio Highlights / Portfolio Highlights detail

Time: 2022-05-07

Source: Viva Biotech

[Abstract]:VVN539 is the next clinical stage project of VivaVision after VVN001, which is expected to become a competitive ophthalmic drug globally.

VivaVision, an innovative ophthalmic drug company which invested and incubated by Viva BioInnovator, announced that it has submitted a Phase II clinical trial application for the new drug VVN539 for the treatment of open-angle glaucoma to the FDA on May 5, 2022, and will start the clinical study in June 2022.

VVN539 is a new generation, dual-targeted IOP-lowering drug that acts on the trabecular meshwork of the eye to increase the outflow of aqueous humor, thereby reducing IOP. In preclinical animal models, VVN539 has shown excellent IOP-lowering efficacy.

Previous Page：AIxplorerBio Entered A Broad Collaboration with Baidu’s PaddleHelix to Expedite the Construction of Its AI Small Molecule Drug R＆D Platform Next Page：Portfolio Highlights: Clinical and Financing Updates of QurAlis, Apeiron and QureBio

Back

Media contact: vivapr@vivabiotech.com

This site uses cookies and your privacy choices are important to us

We use cookies to improve the user experience and to analyze website traffic. By clicking "Accept", you consent to the use of cookies on our website, such as cookies policies.